Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial
Open Access
- 27 September 2024
- journal article
- research article
- Published by Elsevier in Journal of Infection
- Vol. 89 (6) , 106285
Abstract
No abstract availableKeywords
Funding Information
- Novavax Inc
This publication has 22 references indexed in Scilit:
- Validation of a severe acute respiratory syndrome coronavirus 2 microneutralization assay for evaluation of vaccine immunogenicityJournal of Virological Methods, 2024
- Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373Vaccine, 2023
- Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in AdolescentsJAMA Network Open, 2023
- Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trialNature Communications, 2023
- Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trialThe Lancet HIV, 2022
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trialThe Lancet HIV, 2021
- Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort studyThe Lancet HIV, 2021
- Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunctionNature Medicine, 2006
- Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral loadVaccine, 2000
- Accelerated Loss of Antibody to Hepatitis B Surface Antigen among Immunodeficient Homosexual Men Infected with HIVNew England Journal of Medicine, 1987